Swedish Orphan Biovitrum reorganizes its Executive Management Team and strengthen the Business Development functions
Stockholm, Sweden February 22, 2011 - Swedish Orphan Biovitrum (STO:SOBI) today announced changes to its management team and a strengthening of its Business Development function.
New appointments are: Lars Sandstöm CFO, Stefan Fraenkel, Head of Business Development and Åsa Stenqvist Vice President for IR and Communication, A new function is created; Merger and Acquisitions headed by Göran Arvidson, VP who will continue to be a member of the management team and report to the CEO in his new role. In addition Sylvain Forget, Regional Director Western Europe and General Manager Sobi France will join the management team to increase the international focus. The Business Development function, under the new VP Stefan Fraenkel, will increase its competence capabilities to include additional staffing. The new Executive Management Team will consist of the following persons: Kennet Rooth, CEO, (temp) Lars Sandström, CFO Göran Arvidson, VP, Mergers and Acquisitions Anders Edvell, VP Marketing and Sales Peter Edman, VP Research and Development Stefan Fraenkel, VP Business Development Åsa Stenqvist, VP, IR and Communication, (temp) Lena Nyström, VP, Operations Maria Berggren, VP Human Resources Fredrik Berg, VP Legal & IP, Security, Environment and Risk Management Sylvain Forget, Regional Director Western Europe "The changes illustrate our commitment to a growth strategy built both on products coming from our very exciting late stage pipeline as well as aggressively pursuing partnerships with other pharmaceutical and biotech companies, in licensing activities and acquisitions. In addition, the broadening of the Executive Management Team is a reflexion of our international focus. Many of the team members have vast international experience. I am both proud and pleased to have the new team in place and I am convinced this team will deliver on expectations," says Sobi's CEO Kennet Rooth. This also means that Erik Kinnman, formerly VP IR and Communications will leave Sobi to pursue other career opportunities. "I thank Erik for his contributions to the creation of Sobi and wish him the best of luck in his future career" About Swedish Orphan Biovitrum (Sobi) Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical company with an international market presence. The company is focused on providing and developing specialist pharmaceuticals for rare disease patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipe-line. The company focus on the areas: hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer and inherited metabolic disorders. Swedish Orphan Biovitrum had pro-forma revenues 2009 of about 2 BSEK and approximately 500 employees. The head office is located in Stockholm and the share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information please visitwww.sobi.com. For more information please contact: Swedish Orphan Biovitrum AB (publ): Kennet Rooth, CEO (temp) Phone: +46 8 697 20 00 Swedish Orphan Biovitrum may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on February 22, 2011 at 8 a.m. CET.